Last reviewed · How we verify
Ex vivo immunotherapy
At a glance
| Generic name | Ex vivo immunotherapy |
|---|---|
| Also known as | Aplastic Anemia, ex vivo Immunotherapy |
| Sponsor | Shenzhen Zhongxing Yangfan Biotech Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (PHASE2)
- Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01) (NA)
- Natural Killer-cell Therapy for Acute Myeloid Leukemia (PHASE1, PHASE2)
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG) (PHASE1)
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (PHASE1)
- PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PHASE1)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- CARv3-TEAM-E T Cells in Glioblastoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ex vivo immunotherapy CI brief — competitive landscape report
- Ex vivo immunotherapy updates RSS · CI watch RSS
- Shenzhen Zhongxing Yangfan Biotech Co. Ltd. portfolio CI